Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proton beam therapy for iris melanomas.

L Lumbroso-Le Rouic1, S Delacroix, R Dendale

  • 1Department of ophthalmology, Institut Curie, Paris, France. livia.lumbroso@ curie.net

Eye (London, England)
|November 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018).

ESMO real world data and digital oncology·2026
Same author

Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

ESMO open·2025
Same author

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Real-world first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer: the CAPSTAN CRC study.

ESMO open·2022
Same author

Secondary orbital exenteration for conjunctival melanoma: A study of 25 cases.

Journal francais d'ophtalmologie·2021
Same author

First proton minibeam radiation therapy treatment plan evaluation.

Scientific reports·2020
Same journal

Vaginal mucosa as an alternative eye-covering tissue in modified osteo-odonto-keratoprosthesis.

Eye (London, England)·2026
Same journal

Prevalence of and risk factors for diabetic retinopathy: The Thessaloniki Eye Study.

Eye (London, England)·2026
Same journal

Eyelid margin tick masquerading as a naevus in a child.

Eye (London, England)·2026
Same journal

Full-thickness macular penetration by welding laser injury.

Eye (London, England)·2026
Same journal

Incidence and characteristics of newly formed polypoidal lesions in polypoidal choroidal vasculopathy.

Eye (London, England)·2026
Same journal

Traumatic intravitreal egg-shaped hematoma.

Eye (London, England)·2026
See all related articles

Proton beam therapy effectively controls localized iris melanomas, preserving the eye and preventing metastasis. This treatment offers excellent local tumor control for selected patients.

Area of Science:

  • Ophthalmology
  • Radiation Oncology
  • Medical Physics

Background:

  • Iris melanomas are rare ocular tumors requiring effective treatment strategies.
  • Preserving ocular structures and function is a primary goal in managing iris melanomas.

Purpose of the Study:

  • To evaluate the efficacy of proton beam irradiation for localized iris melanomas.
  • To assess local control, eye preservation, and systemic outcomes following proton therapy.

Main Methods:

  • Retrospective review of 21 patients with iris melanoma treated with proton beam therapy (60 Gy in four fractions).
  • Exclusion criteria included ciliary body involvement or extrascleral invasion.
  • Median follow-up was 33 months.

Main Results:

Related Experiment Videos

  • Excellent local tumor control with no ocular relapses or secondary enucleations observed.
  • All patients remained alive with no confirmed metastatic disease.
  • Tumor response included partial regression in 75% of cases within 2 years. Cataract formation was the main complication (45%).

Conclusions:

  • Proton beam therapy is a viable option for selected localized iris melanomas, achieving high rates of local control and eye preservation.
  • Further research with larger cohorts is warranted to confirm these findings.